http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades
Alvaro Gregorio Morales Taboad,Pablo Lozano Lominchar,Lorena Martin Roman,Pilar Garcia-Alfonso,Andres Jesus Munoz Martin,Jose Antonio Blanco Rodriguez,Jose Manuel Asencio Pascual 한국간담췌외과학회 2021 Annals of hepato-biliary-pancreatic surgery Vol.25 No.2
In the last two decades, pancreatic cancer has been undergoing important changes in its perioperative management due to the great interest in multidisciplinary management and preoperative multimodal therapy, which in numerous studies have shown promising clinical results. Although the standard of treatment for resectable pancreatic ductal adenocarcinoma (PDAC) today is surgery followed by adjuvant therapy, as it is a biologically aggressive disease, even with complete resection, it has high rates of local and distant relapse. Several retrospective and prospective phase I/II studies have opened the window for neoadjuvant therapy with chemotherapy (CT), chemoradiotherapy (CRT), or both, as an alternative treatment for resectable pancreatic cancer, with promising results. Neoadjuvant therapy could has some advantages, including early administration of systemic treatment, in vivo assessment of response to treatment, increase resectability rate in borderline patients, increase resection rate with negative margin and survival benefit. While it seems clear that even potentially resectable disease would benefit from preoperative multimodal therapy, the optimal neoadjuvant therapeutic strategy is still controversial and currently there are only recommendations for neoadjuvant treatment, in clinical guidelines such as the NCCN and ESMO, for borderline and/or locally advanced PDAC. This review provides an overview of recent studies available and how they relate to systemic treatment of resectable PDAC in the neoadjuvant setting.
Neoadjuvant therapy impact in early pancreatic cancer: “bioborderline” vs. “non-bioborderline”
Alvaro Gregorio Morales Taboad,Pablo Lozano Lominchar,Maria Fernandez Martinez,Pilar Garcia-Alfonso,Andres Munoz Martin,Jose Manuel Asencio 한국간담췌외과학회 2022 Annals of hepato-biliary-pancreatic surgery Vol.26 No.4